A Phase I Randomized, Observer-blind, Controlled, Dose Escalation Trial of the Safety and Tolerability of a Single Intramuscular Dose of a PAL Adjuvant (FB-631) Co-administered With Seasonal TIV (2013-2014) in Healthy Adults

Trial Profile

A Phase I Randomized, Observer-blind, Controlled, Dose Escalation Trial of the Safety and Tolerability of a Single Intramuscular Dose of a PAL Adjuvant (FB-631) Co-administered With Seasonal TIV (2013-2014) in Healthy Adults

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Oct 2014

At a glance

  • Drugs GSK 1536489A (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions
  • Sponsors Folia Biotech
  • Most Recent Events

    • 14 Oct 2014 Status changed from recruiting to active, no longer recruiting, according to the ClinicalTrials.gov record.
    • 22 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top